In urological cancers, several small molecule inhibitors targeting MET have been used in PC and RCC in clinical trials, and cavozantinib is used as a major agent targeting MET and VEGFR in patients with advanced RCC [90,91,108,109]. This evidence concerns the gene KDR and renal cell carcinoma.